| Literature DB >> 33449410 |
Fatma Eser1, Bircan Kayaaslan1, Rahmet Güner1, Imran Hasanoğlu1, Ayse Kaya Kalem1, Adalet Aypak2, Esragul Akinci2.
Abstract
AIMS: The impact of ongoing PCR positivity on COVID-19 patients and the strategy and period of isolation were not fully understood. We aimed to investigate the factors that cause prolonged PCR positivity and its clinical impact on COVID-19 infection. In addition, we searched for an answer on what length of time would be best for isolation.Entities:
Mesh:
Year: 2021 PMID: 33449410 PMCID: PMC7995230 DOI: 10.1111/ijcp.14025
Source DB: PubMed Journal: Int J Clin Pract ISSN: 1368-5031 Impact factor: 3.149
Demographic and clinical characteristics of patients based on the duration of negative PCR test results after symptom onset
| Days of first negative PCR result test after symptom onset | |||
|---|---|---|---|
| 0‐14 days (n = 289) | ≥15 days (n = 50) |
| |
| Median (IQR) | Median (IQR) | ||
| Age (y) (median [min‐max]) | 45 [18‐93] | 45 [19‐86] | .16 |
| Symptoms duration on admission | 3 (1‐4) | 7 (3‐10) |
|
| Total symptom duration | 7 (5‐11) | 7 (4‐10) | .77 |
| Duration of hospitalisation | 10 (8‐13) | 9 (7‐12) | .20 |
Bold values are statistical significant
Laboratory analyses in all patients based on day of first negative PCR test after symptom onset
| Laboratory test | Day of first negative PCR result test after symptom onset | |||
|---|---|---|---|---|
| All patients (n = 339) | 0‐14 days (n = 289) | ≥15 days (n = 50) |
| |
| Median [min‐max] | Median [min‐max] | Median [min‐max] | ||
| White blood cell count ‐ ×109/L | 5255 [120‐59290] | 5205 [120‐59290] | 5435 [2920‐18760] | .47 |
| Neutrophil count ‐ ×109/L | 3270 [200‐16460] | 3280 [200‐13410] | 3225 [1430‐16460] | .84 |
| Lymphocyte count ‐ ×109/L | 1180 [150‐7360] | 1170 [150‐7360] | 1265 [330‐3090] | .49 |
| Monocyte count‐ ×109/L | 330 [40‐1460] | 330 [40‐1460] | 330 [130‐670] | .79 |
| Haemoglobin ‐ g/L | 13.8 [7.1‐17] | 13.8 [7.1‐17] | 13.8 [10.9‐16.4] | .65 |
| Platelet count ‐ ×109/L | 206 500 [13000‐436000] | 209 000 [13000‐436000] | 198 000 [14500‐406000] | .40 |
| Urea | 26 [11‐52] | 27 [11‐52] | 25 [13‐45] | .55 |
| Creatinine ‐ μmol/L | 0.8 [0.1‐46753] | 0.8 [0.1‐46753] | 0.8 [0.5‐43831] | .75 |
| AST, U/L | 24 [7‐500] | 24 [7‐500] | 26 [11‐74] | .78 |
| ALT, U/L | 28 [7‐634] | 28 [7‐634] | 27 [9‐113] | .96 |
| Albumin ‐ g/L | 45 [30‐54] | 45 [33‐54] | 44 [30‐50] |
|
| Creatine Kinase ‐ μ/L | 93 [12‐5395] | 93.5 [12‐5395] | 93 [20‐860] | .71 |
| LDH U/L | 218 [106‐697] | 218 [106‐697] | 211 [160‐646] | .77 |
| C‐reactive protein ‐ mg/L | 0.009 [0.00007‐0.9] | 0.009 [0.00007‐0.9] | 0.009 [0.0001‐0.3] | .35 |
| Procalcitonin (PCT) μg/L | 0 [0‐2] | 0.03 [0‐1.3] | 0.03 [0‐2] | .84 |
| Ferritin, μg/L | 118.5 [1‐1566] | 118 [1‐1023] | 178 [10‐1566] | .30 |
| D‐dimer ‐ μg/L | 0.4 [0‐35.2] | 0.4 [0‐35.2] | 0.4 [0‐2] | 1.00 |
| Fibrinogen ‐ g/L | 3.1 [1.3‐291] | 3 [1.3‐291] | 3.2 [2‐8.5] | .28 |
| IL‐6, pg/mL | 12.3 [2‐289] | 11.3 [2‐289] | 24.5 [4.3‐80] | .13 |
Bold values are statistical significant
Factors associated with duration of prolonged PCR positivity of SARS‐CoV‐2 RNA from symptom onset
| Multivariate analysis | |||
|---|---|---|---|
| OR | 95% CI |
| |
| Age (y) | 1.022 | 1.002‐1.042 |
|
| Sex (male) | 0.783 | 0.385‐1.593 | .500 |
| Symptoms duration on admission | 1.456 | 1.306‐1.624 |
|
| Total symptom duration | 1.101 | 0.994‐1.220 | .065 |
| Consolidation | 0.580 | 0.219‐1.532 | .271 |
| Albumin ‐ g/L | 0.899 | 0.807‐1.003 | .056 |
FIGURE 1Duration of symptoms and PCR negativity for patients with COVID‐19
FIGURE 2Correlation between symptom duration and PCR negativity duration after symptom onset in COVID‐19 patients